Groupe d'Etude en Oncologie du Quebec

Title	A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer.
Protocole ID	TIGOS
ClinicalTrials.gov ID	NCT06646276
Cancer Type(s)	Small Cells - Lung
Phase	Phase III
Stage
Study Type	Clinical
Drug	BMS-986489 (BMS-986012+Nivolumab) en association avec carboplatine + étoposide versus atézolizumab en association avec carboplatine + étoposide
Institution	INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE DE QUEBEC - UL
City
Principal Investigator	Dr. Marie-Hélène Denault
Coordinator	Marie-Ève Morneau 418-656-8711 poste 2690
Status	Recruiting
Activation Date
Eligibility Criteria	Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale. Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system
Exclusion Criteria	Participants have already received certain types of treatment for extensive stage small cell lung cancer Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy Other protocol-defined Inclusion/Exclusion criteria apply.

Groupe d'étude en oncologie du Québec